Figure 1

Association analysis between polymorphisms of NER pathway and outcomes of platinum-based chemotherapy in lung cancer. Red line means the significance level after strict Bonferroni correction (P < 2.89 × 10⁻⁴ ((0.05/173)), black line means the significance level of 0.05. (A) association analysis in all patients; (B) association analysis in subgroup of adenocarcinoma; (C) association analysis in subgroup of squamous cell carcinoma; (D) association analysis in subgroup of paclitaxel combined with cisplatin regimen; (E) association analysis in subgroup of gemcitabine combined with cisplatin regimen; (F) association analysis in subgroup of navelbine combined with cisplatin regimen; (G) association analysis in subgroup of age ≤ 58; (H) association analysis in subgroup of age > 58. The genes analyzed in this study is as follow: 1, XPC; 2, RAD23B; 3, ERCC2; 4, GTF2H1; 5, XPA; 6, ERCC5; 7, ERCC1; 8, ERCC4; 9, ERCC8; 10, ERCC6; 11, DDB2; 12, LIG1; 13, CDK7; 14, CCNH; 15, MNAT1; 16, RPA1; 17, RPA2; 18, RFC1; 19, RFC2; 20, POLD1; 21, POLD2; 22, POLD3; 23, POLD4; 24, POLE; 25, POLE2; 26, GTF2H3; 27, GTF2H4.